Serhat TUNAR -TDO- Clinical trials of the drug Avigan, which has been observed to accelerate the recovery of Covid-19 patients, have begun in Japan. Avigan, developed by Toyama Chemical for influenza treatment, will be tried in 100 patients by the end of June.
The origin of the new type of coronavirus was reported in China, where patients who received the drug in question recovered in a much shorter time than those who did not.
In the clinical trials in Japan, based on these reports, the drug will be given to mild pneumonia patients between the ages of 20 and 74 for 14 days. Pregnant women will not be included in the clinical trial because of side effects that have occurred in previous animal experiments.
This drug, produced antiviral for the treatment of Influenza, needs to be passed through a series of tests and approved before it can be given to Covid-19 patients.